Brian Daniels

Biography

 Dr. Daniels is a highly regarded drug developer with over two decades of leadership experience in research, clinical development and medical affairs. His therapeutic experience extends across a broad range, including immunology, pulmonary, virology, cardiovascular and oncology. He joined 5AM Ventures as a Venture Partner in 2014 and is a senior advisor to the Boston Consulting Group. In addition to Spyryx, Dr. Daniels is a board member of Novo Nordisk, Nohla Therapeutics, and Armaron Bio. He also sits on advisory boards for a number of companies. Prior to joining 5AM, Dr. Daniels was Senior Vice President for Global Development and Medical Affairs at Bristol-Myers Squibb where he directed the development of numerous innovative medicines. More than ten of the medicines under his guidance achieved sales greater than $1 billion annually. Earlier in his career, he also had development experience at Merck and Genentech. Dr. Daniels received BS and MS degrees from the Massachusetts Institute of Technology and his MD from Washington University in St. Louis. He trained in internal medicine at New York Hospital and rheumatology/immunology at University of California – San Francisco.

Research Interest

 Genetics and Immunology